PD173074

For research use only.

Licensed by Pfizer Catalog No.S1264

69 publications

PD173074 Chemical Structure

Molecular Weight(MW): 523.67

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 98 In stock
USD 70 In stock
USD 120 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's PD173074 has been cited by 69 publications

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
Targets
FGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
~25 nM 100 nM-200 nM
In vitro

PD173074 is an ATP-competitive inhibitor of FGFR1 with Ki of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. [1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. [2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. [3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1581 M2f1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXH[ZJKSzVyPUCuNFEzOjVizszN MWTTRW5ITVJ?
KG-1 M335emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TQUmlEPTB;MD6wOVEzQSEQvF2= MX3TRW5ITVJ?
MFM-223 M{\yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnpRlhEUUN3ME2wMlIyPTd4IN88US=> M4n1ZXNCVkeHUh?=
EoL-1-cell MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljNTWM2OD1yLkOyPVg1KM7:TR?= NWLkeHVZW0GQR1XS
ECC10 NX7Fb3hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\1[JMzUUN3ME2wMlM{QDl6IN88US=> Mk[1V2FPT0WU
H-EMC-SS MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfXfI5PUUN3ME2wMlM1PzF3IN88US=> MVjTRW5ITVJ?
AN3-CA NVvCW|BrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLvTWM2OD1yLkSwNVM{KM7:TR?= NXOxR2dlW0GQR1XS
HuO-3N1 NFjYXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwNUS2OVMh|ryP NXHhSY1yW0GQR1XS
RT-112 NULMUWZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwNUS3NFEh|ryP MULTRW5ITVJ?
NEC8 NWnyVGpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwNU[yPFkh|ryP M4Xnc3NCVkeHUh?=
D-263MG NYPmSZluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe2TWM2OD1yLkexNVU6KM7:TR?= NIXkN|VUSU6JRWK=
SW962 NVTrNnJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;XdWlEPTB;MD63PFk5QCEQvF2= Ml3XV2FPT0WU
BV-173 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3FcIlKSzVyPUCuPFQ3OjNizszN M2rsenNCVkeHUh?=
MFE-280 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF76S2lKSzVyPUCuPFU5PzJizszN NHjwW2JUSU6JRWK=
HuH-7 NGrM[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPnV|JKSzVyPUGuNlQ1PjRizszN MWfTRW5ITVJ?
RS4-11 MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTwbJI{UUN3ME2xMlM{QDh4IN88US=> NFG0UmNUSU6JRWK=
DMS-114 NWXDUYQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwM{[3N|ch|ryP NH\Jfm9USU6JRWK=
MSTO-211H MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLwTWM2OD1zLkS3N|c5KM7:TR?= MmH1V2FPT0WU
DU-145 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFwNUiyNVch|ryP MnrlV2FPT0WU
A172 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFwN{CzOVUh|ryP NXTCOGdFW0GQR1XS
SBC-1 NGrTZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrWVoNKSzVyPUKuNFk1KM7:TR?= MYXTRW5ITVJ?
H9 M3;Temdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVztOY85UUN3ME2yMlE1OzB4IN88US=> NI\XUY1USU6JRWK=
NCI-SNU-1 NX;JZ|M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXJd4ZPUUN3ME2yMlE5Ozl2IN88US=> NFHHbIhUSU6JRWK=
NCI-H720 MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTJwMkGyPFMh|ryP M1rCPXNCVkeHUh?=
HCC2218 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHJTWM2OD1{LkO3PVM6KM7:TR?= M1TIdXNCVkeHUh?=
G-401 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7VeItHUUN3ME2yMlQ4OTh7IN88US=> M3Lkd3NCVkeHUh?=
MPP-89 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zyS2lEPTB;Mj60PFM3PCEQvF2= MnXwV2FPT0WU
697 NFOzVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37aOWlEPTB;Mj62OVM{OSEQvF2= Mlj5V2FPT0WU
KARPAS-45 NFy4SldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rWRmlEPTB;Mj63NFc1PyEQvF2= MVTTRW5ITVJ?
MG-63 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvGfmxGUUN3ME2yMlk1OjZ{IN88US=> MXLTRW5ITVJ?
NTERA-S-cl-D1 NHXJRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL2UWVKSzVyPUOuNFM1PzJizszN NVqwZZNRW0GQR1XS
G-402 NHnPTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LXfGlEPTB;Mz6xNlczPyEQvF2= MVHTRW5ITVJ?
NKM-1 M3TvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDYTWM2OD1|LkGzOVY1KM7:TR?= NVu2c3dXW0GQR1XS
RH-18 MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPoTWM2OD1|LkG5OVk5KM7:TR?= M361RXNCVkeHUh?=
NCI-H1092 Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zLU2lEPTB;Mz6xPVY6KM7:TR?= M4n2THNCVkeHUh?=
RPMI-8226 NVTwTXZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3aTXBGUUN3ME2zMlI{PDR5IN88US=> M4jZ[XNCVkeHUh?=
GAMG NVrXSnRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELjemxKSzVyPUOuOFY2PzZizszN MlTlV2FPT0WU
HH MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHIdIo6UUN3ME2zMlQ4Pjd4IN88US=> NIDkR3lUSU6JRWK=
RO82-W-1 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[4c|JyUUN3ME2zMlQ6QDV3IN88US=> NGPWUGJUSU6JRWK=
CCRF-CEM MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH6UnhJUUN3ME2zMlUxPDh6IN88US=> M{PUOHNCVkeHUh?=
NBsusSR MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7vTWM2OD1|Lk[zPVY6KM7:TR?= NXHWToFNW0GQR1XS
CHL-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf5NGZKSzVyPUOuOlU4QTlizszN M{LmfHNCVkeHUh?=
LK-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXnOmQ{UUN3ME2zMlY4OTN|IN88US=> NG\Zb|RUSU6JRWK=
Hs-578-T MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3tR|h3UUN3ME2zMlY4QDd|IN88US=> NV\WcHhJW0GQR1XS
CTB-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;GVGlEPTB;Mz64NFA2OSEQvF2= M1jWR3NCVkeHUh?=
ES5 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjKWmRKSzVyPUOuPFM3OzdizszN NYPn[HZ1W0GQR1XS
A204 NIDQZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LDcmlEPTB;Mz65NlA4PSEQvF2= NX;ZNYRWW0GQR1XS
SW780 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHBZplKSzVyPUOuPVIzPDVizszN NVP6SYtNW0GQR1XS
EW-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTNwOUi5NlMh|ryP MkXTV2FPT0WU
A704 M2S5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K2VGlEPTB;ND6yPFczOyEQvF2= NVHKdItHW0GQR1XS
LU-139 NEXveI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTRwM{G1N|Qh|ryP MnvsV2FPT0WU
CAL-72 NEHNTHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXuzNXNKUUN3ME20MlQyPzR4IN88US=> M4naO3NCVkeHUh?=
D-336MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTqTWM2OD12LkS2PFE4KM7:TR?= Mlu2V2FPT0WU
LAMA-84 NE\teWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PjeWlEPTB;ND61N|MyKM7:TR?= MnHOV2FPT0WU
GI-ME-N NVzMZlVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTRwNUS4NUDPxE1? NIKxZ3hUSU6JRWK=
KM-H2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTRwNUWyNlIh|ryP NWTURoZJW0GQR1XS
NCI-H209 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\WWWpKSzVyPUSuOVgzQDNizszN MnfiV2FPT0WU
IGROV-1 Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fGcmlEPTB;ND64O|E3QCEQvF2= Mo\zV2FPT0WU
L-363 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTRwOU[2OlUh|ryP MkHwV2FPT0WU
SK-MEL-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XvfGlEPTB;NT6yOFA3KM7:TR?= MnzVV2FPT0WU
HuO9 MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nqcGlEPTB;NT6zPFg1OyEQvF2= MV3TRW5ITVJ?
NOS-1 NFvUdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfIenlvUUN3ME21MlczQTJ5IN88US=> NVjOd3hTW0GQR1XS
NCI-H1770 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfQTWM2OD13Lkm1NFMzKM7:TR?= NX7hU5RPW0GQR1XS
SF126 NEDLdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y5TGlEPTB;Nj6yNVQxPiEQvF2= NGGxeoFUSU6JRWK=
ML-2 M1TTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LY[GlEPTB;Nj6yOFk4PyEQvF2= NELsbYpUSU6JRWK=
CHP-134 NV3UenJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm3TWM2OD14LkK1NVgzKM7:TR?= MXjTRW5ITVJ?
NCI-H1355 NVnkVpdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTZwNEG3N|Mh|ryP M13lb3NCVkeHUh?=
TE-12 NF3Hd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjHTWM2OD14LkeyOlcyKM7:TR?= NYGzO3VuW0GQR1XS
A4-Fuk M2HMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnDVVdKSzVyPU[uO|MyPDJizszN M1rUUnNCVkeHUh?=
MV-4-11 MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHOTWM2OD14Lke2OlI3KM7:TR?= NVPPVo04W0GQR1XS
SK-UT-1 M4m5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjiclY3UUN3ME22MlkyPzh2IN88US=> MXrTRW5ITVJ?
J-RT3-T3-5 M4XncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzCSIlvUUN3ME23MlA4PzZ2IN88US=> MUHTRW5ITVJ?
ME-180 M2Px[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTdwMUC0NFQh|ryP MlHHV2FPT0WU
SK-MEL-28 MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLyTWM2OD15LkO3PFE6KM7:TR?= NHTrWYFUSU6JRWK=
HAL-01 MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3uSZVKSzVyPUeuOFg{PDFizszN NX3CeZpXW0GQR1XS
ES8 MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTdwNkm2NlYh|ryP M2OzN3NCVkeHUh?=
DB NHrm[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljqTWM2OD16LkGxOVA1KM7:TR?= NGrlbXpUSU6JRWK=
SK-NEP-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzBTWM2OD16LkS4NVQ6KM7:TR?= NW\aVJl3W0GQR1XS
COR-L88 M{f4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljnTWM2OD16LkWwPVgyKM7:TR?= NXjmOIFOW0GQR1XS
LB1047-RCC NYrLRlFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRThwNUKyNVIh|ryP NFnJV3dUSU6JRWK=
NCI-H520 M{jq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm5TWM2OD16Lk[yNVU4KM7:TR?= Mkf6V2FPT0WU
SW954 NX\DSJBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHaT4tHUUN3ME24MlY6Pzh4IN88US=> NEfEbYFUSU6JRWK=
TE-6 MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILENodKSzVyPUiuO|UyPDNizszN MmPjV2FPT0WU
D-283MED M3GwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\L[5JDUUN3ME25MlA3PTN2IN88US=> NF2xN3hUSU6JRWK=
DBTRG-05MG MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXJNFdKSzVyPUmuNFk3ODdizszN NIDZfZNUSU6JRWK=
NCI-H446 NIDweXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfz[45KSzVyPUmuNlk2OjZizszN MVzTRW5ITVJ?
HOS M4niS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz0ZVRKSzVyPUmuN|UyOzRizszN NUnaeHh{W0GQR1XS
ES4 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPoVZRKSzVyPUmuOVA2QTVizszN MlTMV2FPT0WU
EW-13 NH3NTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fIN2lEPTB;OT64PVA2PSEQvF2= MYrTRW5ITVJ?
IST-MES1 MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HZeGlEPTB;OT65OFU{PCEQvF2= MVnTRW5ITVJ?
CAS-1 NHLiW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTlwOUe2OVkh|ryP M{HiO3NCVkeHUh?=
EM-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j6SWlEPTB;MUCuNVM6OyEQvF2= M1nkVnNCVkeHUh?=
SW948 NYTqTnVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLBTWM2OD1zMD6xPFgzKM7:TR?= Mnz1V2FPT0WU
OAW-42 NGLMdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:5U2lEPTB;MUCuOVI3PyEQvF2= MVrTRW5ITVJ?
BE-13 NI\ESWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHnZWR5UUN3ME2xNE43PTd4IN88US=> Mm\EV2FPT0WU
KU812 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37uUGlEPTB;MUCuO|M6OSEQvF2= M1PReHNCVkeHUh?=
SK-MEL-30 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nVWmlEPTB;MUCuPFkxOSEQvF2= M2nsfHNCVkeHUh?=
A2780 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFzLkCzNFgh|ryP MV7TRW5ITVJ?
TGBC24TKB MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XDfWlEPTB;MUGuNFc{PyEQvF2= NVK1cVVQW0GQR1XS
GOTO NHLIWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzob4FKSzVyPUGxMlIxQDRizszN NHn6fWlUSU6JRWK=
NCI-H526 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzsTWM2OD1zMT6zPFM4KM7:TR?= MVvTRW5ITVJ?
BHT-101 NUHHNHhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XV[2lEPTB;MUGuOFQ2PiEQvF2= NFz3boNUSU6JRWK=
NCI-H1155 NGqzTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFzLkS5OFch|ryP MVjTRW5ITVJ?
MCF7 M{PJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPzeYJKSzVyPUGxMlYyPjdizszN MVTTRW5ITVJ?
MKN45 NIHOVG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PFZ2lEPTB;MUGuO|k6OyEQvF2= NGTT[ZNUSU6JRWK=
MOLT-16 NYHTWVJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFzLkm2PVIh|ryP NF\mSGdUSU6JRWK=
YH-13 NX7CUJQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzPXZRKSzVyPUGyMlA{PDZizszN MYPTRW5ITVJ?
P12-ICHIKAWA NYr6S5F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nUSWlEPTB;MUKuN|g1PSEQvF2= MkPtV2FPT0WU
GR-ST MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\LW2dKSzVyPUGyMlUzQTVizszN MVPTRW5ITVJ?
CAKI-1 M4HKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTF{Lke5NUDPxE1? NUjGRYVjW0GQR1XS
LXF-289 MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF|LkC4N|Uh|ryP MYPTRW5ITVJ?
MHH-PREB-1 M1TFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C2dWlEPTB;MUOuNlcxPCEQvF2= M1nVXnNCVkeHUh?=
EW-16 NGfIZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF|LkOxPFch|ryP M4fqSHNCVkeHUh?=
NCI-H82 MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHJenRKSzVyPUGzMlQyQTVizszN NV\BPFBzW0GQR1XS
MMAC-SF NVH4blRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vjXGlEPTB;MUOuOFU1PyEQvF2= MU\TRW5ITVJ?
COLO-684 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDLTWM2OD1zMz61N|E5KM7:TR?= M1LqUXNCVkeHUh?=
QIMR-WIL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLITWM2OD1zMz64NVA6KM7:TR?= NVHpcYZpW0GQR1XS
NB69 NXKyT2ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TafGlEPTB;MUOuPVg3QCEQvF2= M3u4OXNCVkeHUh?=
NCI-H2291 MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF2LkS0OVMh|ryP NF31bJRUSU6JRWK=
MKN7 NGDEcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PSOGlEPTB;MUSuOlY4PiEQvF2= M3rWUnNCVkeHUh?=
HDLM-2 M3;sbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF3LkGyPFYh|ryP MlzOV2FPT0WU
A253 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXwTWM2OD1zNT6zPFY6KM7:TR?= NFzTS2JUSU6JRWK=
SK-LU-1 MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTu[HZVUUN3ME2xOU46ODl2IN88US=> NW\SbGVnW0GQR1XS
MEG-01 MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjPWIFKSzVyPUG1MlkyODdizszN NXL0fIdyW0GQR1XS
SK-N-DZ MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7BZWJxUUN3ME2xOU46Ozd4IN88US=> Ml23V2FPT0WU
H4 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7oZnJKSzVyPUG2MlA5QCEQvF2= NWnSemJ2W0GQR1XS
LU-65 NXPnfFFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF4LkOzPFQh|ryP NVjBeYtFW0GQR1XS
NCI-H1048 NIfheoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTPT2dKSzVyPUG2MlUyPjVizszN NGrFRmJUSU6JRWK=
LCLC-97TM1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmmyTWM2OD1zNj61PFg6KM7:TR?= MlHCV2FPT0WU
CAL-120 NVXCTIVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF4Lkm4O|kh|ryP NEHWUGFUSU6JRWK=
LU-134-A MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF5LkOzPVEh|ryP M1rEc3NCVkeHUh?=
SK-MEL-1 M1qzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfycpRVUUN3ME2xO{44OTJ5IN88US=> NHrNT5lUSU6JRWK=
NCI-H69 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLTUJJzUUN3ME2xO{46OzB5IN88US=> M1HPfXNCVkeHUh?=
MC116 NHPyeGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7JUWNKSzVyPUG3Mlk4PSEQvF2= MkLJV2FPT0WU
UMC-11 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP5TWM2OD1zOD6xO|g5KM7:TR?= MlmwV2FPT0WU
HCC1395 M2jhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTF6LkSzNFEh|ryP NWD0TlZ1W0GQR1XS
no-10 M{f6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj0bXJXUUN3ME2xPE43Ozh6IN88US=> MkTsV2FPT0WU
NY NVzPcXp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HSUGlEPTB;MUmuNFgxQSEQvF2= NYjpe2tLW0GQR1XS
OS-RC-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTF7LkGyOVIh|ryP M3vBRXNCVkeHUh?=
D-423MG NUmzcI43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDXR4JKSzVyPUG5MlM6PTJizszN M2r1UnNCVkeHUh?=
LC-2-ad NFP2enFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF7Lke2NVIh|ryP NF:5S5dUSU6JRWK=
DU-4475 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{mxTmlEPTB;MUmuPFg2OiEQvF2= NVP1U5FsW0GQR1XS
YKG-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T6O2lEPTB;MUmuPVYzKM7:TR?= NVjaSJltW0GQR1XS
HCC1569 Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnsTWM2OD1{MD6yOlI1KM7:TR?= M1vTOHNCVkeHUh?=
TYK-nu M{ezb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnmbFFYUUN3ME2yNE4zQDR5IN88US=> M{nOeXNCVkeHUh?=
DEL NGC0VpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJyLkm4NFgh|ryP NUjCbVhSW0GQR1XS
MHH-ES-1 NXXjXphCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJzLkO1PVch|ryP MkWxV2FPT0WU
KARPAS-299 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjBWWlKSzVyPUKxMlUzQSEQvF2= MWXTRW5ITVJ?
CTV-1 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LjbGlEPTB;MkGuOlE4OiEQvF2= NFnjOmhUSU6JRWK=
NCI-H2452 M4LlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPRTWM2OD1{Mj62Olc4KM7:TR?= MmHXV2FPT0WU
D-566MG MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3leHBLUUN3ME2yNk44PjBzIN88US=> M2DjR3NCVkeHUh?=
EFO-27 NHzHSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G4NGlEPTB;MkOuNFY2OSEQvF2= MV3TRW5ITVJ?
NCI-H596 NYP2[JlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTOZ5RKSzVyPUKzMlg2OjdizszN MnXoV2FPT0WU
KS-1 NHXISXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJ2LkK3OVkh|ryP MULTRW5ITVJ?
8305C MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;DTWM2OD1{ND60NFQ2KM7:TR?= MX\TRW5ITVJ?
A427 M33mWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fMe2lEPTB;MkWuNFMzOyEQvF2= Ml61V2FPT0WU
COLO-800 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP1b4ZKSzVyPUK1MlExPjFizszN MXHTRW5ITVJ?
SJRH30 NEHFdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nV[2lEPTB;MkWuN|kxQCEQvF2= M2W2enNCVkeHUh?=
MEL-HO NXrVc|BwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvqemtKSzVyPUK1MlQ{OTlizszN NYfMTIx5W0GQR1XS
FTC-133 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C1PWlEPTB;MkWuPFE5PiEQvF2= NF\LR4pUSU6JRWK=
SF295 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG4TWM2OD1{Nj6yPVYh|ryP NVP5ZnVFW0GQR1XS
SW1710 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\6TWM2OD1{Nj60NVI{KM7:TR?= NEKwco1USU6JRWK=
EFM-19 NG[x[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofWTWM2OD1{Nj64NVQ2KM7:TR?= NGD4RXBUSU6JRWK=
NB10 NV:zNFhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:0SGlWUUN3ME2yPE4zOjl5IN88US=> MlfEV2FPT0WU
TK10 M2L2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7BdmFyUUN3ME2yPE4zOzl7IN88US=> M4jGfnNCVkeHUh?=
D-502MG MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJ6LkSg{txO M{TsbHNCVkeHUh?=
EW-18 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFruTHRKSzVyPUK4MlQ{QDZizszN M4PEWHNCVkeHUh?=
VMRC-RCZ NH[wbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJ6Lkm0NUDPxE1? M4m2c3NCVkeHUh?=
Ca9-22 NGfJRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TvXWlEPTB;MkmuOFU2PyEQvF2= NUHXb45iW0GQR1XS
KYSE-70 M4PrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDBPIZxUUN3ME2yPU42Pzh4IN88US=> Mkf5V2FPT0WU
A101D NYWxfZFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJ7Lk[0O|Ih|ryP MX\TRW5ITVJ?
WM-115 NV7oXmVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fQXGlEPTB;MkmuO|YxPyEQvF2= NGHCd5pUSU6JRWK=
HCC2157 MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjvTWM2OD1{OT64PFA4KM7:TR?= NWjwb484W0GQR1XS
TE-9 NITHboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJ7Lki4OlUh|ryP MVnTRW5ITVJ?
K-562 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\3WGlEPTB;M{CuNFk{OyEQvF2= NHP1bHZUSU6JRWK=
SN12C NWfJbHRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHGblZKSzVyPUOwMlE1OjZizszN NVLVfJJIW0GQR1XS
ESS-1 NXi5SVZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\mTWM2OD1|MD60O|U6KM7:TR?= MVHTRW5ITVJ?
K5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTNyLke2OEDPxE1? M3PMZ3NCVkeHUh?=
J82 NEDUZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDhTWM2OD1|MT6wPFk4KM7:TR?= NH3VdJpUSU6JRWK=
HOP-92 NXvZRol4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi5THBKSzVyPUOxMlEyOTFizszN M2rNTXNCVkeHUh?=
NCI-H2228 NF2xPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fqRmlEPTB;M{GuN|I6PiEQvF2= MXTTRW5ITVJ?
OCI-AML2 NYX3OYVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:zTWM2OD1|MT6zOlEh|ryP NX7FbI4zW0GQR1XS
NCI-SNU-5 Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHrSnlKSzVyPUOxMlgyOzdizszN NHzx[otUSU6JRWK=
A3-KAW NIPrSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33JNWlEPTB;M{GuPVI1OyEQvF2= MX7TRW5ITVJ?
LCLC-103H Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\IXGpKSzVyPUOyMlAyPzFizszN MWnTRW5ITVJ?
KY821 NVfQ[oFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3FXpFzUUN3ME2zNk43QDh2IN88US=> MX7TRW5ITVJ?
JVM-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PvWWlEPTB;M{KuPVA4QSEQvF2= M2XnUHNCVkeHUh?=
Mo-T NHLNPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TxU2lEPTB;M{OuNVAxPSEQvF2= MWXTRW5ITVJ?
IA-LM NGqzeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTN|LkK3OUDPxE1? MVzTRW5ITVJ?
C8166 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH1N2lKSzVyPUOzMlMyQTJizszN M4DFSXNCVkeHUh?=
TCCSUP NV7weog5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTiUJd6UUN3ME2zN{41OzB5IN88US=> NHr4PVdUSU6JRWK=
JEG-3 MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF24bZdKSzVyPUOzMlQ4PjhizszN NGLUOpNUSU6JRWK=
MS-1 M{XudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rQ[2lEPTB;M{OuOVU2OSEQvF2= MX7TRW5ITVJ?
NCI-H1304 M4X5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG5[nJKSzVyPUOzMlU4OjVizszN Mo\PV2FPT0WU
Ramos-2G6-4C10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uzcmlEPTB;M{SuNFM{PSEQvF2= MVjTRW5ITVJ?
MDA-MB-453 M4XCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXCOIxKSzVyPUO0MlY{QTVizszN MnuyV2FPT0WU
KYSE-520 NUP6Nol[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHoTIpKSzVyPUO0MlcyQDFizszN NX\lNmF7W0GQR1XS
SW900 MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e0NmlEPTB;M{SuPFEyPSEQvF2= NVzLXoU1W0GQR1XS
HCC2998 M2fCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ywW2lEPTB;M{WuNVUzQSEQvF2= NET0bFRUSU6JRWK=
A2058 NELoflFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTN3Lk[wOlEh|ryP MlvGV2FPT0WU
OVCAR-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;ETWM2OD1|Nj6yNFQ2KM7:TR?= NITnclRUSU6JRWK=
MOLT-4 NWn2VJhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvhU2JQUUN3ME2zOk4zOjl2IN88US=> NV6wV2E5W0GQR1XS
CAPAN-1 NV3FRpdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHjNG9KSzVyPUO2MlQ3QTlizszN MULTRW5ITVJ?
SCC-9 MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPKNXZ[UUN3ME2zO{41ODJ5IN88US=> NVL5Vmt4W0GQR1XS
SF268 NF3Odm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v4eWlEPTB;M{iuN|Q{OyEQvF2= NXXUdHlpW0GQR1XS
HGC-27 NUXPe2QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHVfm9VUUN3ME2zPE4{PzFzIN88US=> MmLzV2FPT0WU
DOHH-2 NFHUWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOzTWM2OD1|OD63NVU5KM7:TR?= MmHHV2FPT0WU
KE-37 NVK4XWRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLFTWM2OD1|OD65PFI5KM7:TR?= M2LIe3NCVkeHUh?=
MOLT-13 M3OwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn3TWM2OD1|OT6yOVAzKM7:TR?= NFHjfIZUSU6JRWK=
ES1 NHPYU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzHW5lNUUN3ME2zPU4{QDVizszN NXjNb3c4W0GQR1XS
SK-OV-3 M1e1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDrNmlKSzVyPUO5Mlk3PDNizszN MnW0V2FPT0WU
SNU-449 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3juXmlEPTB;NECuNFc3PCEQvF2= MV;TRW5ITVJ?
KYSE-510 MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq0c25KSzVyPUSwMlEzQTVizszN M1fhfnNCVkeHUh?=
HL-60 NILWWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDyZZJKSzVyPUSwMlk4QDNizszN NVu5[oMzW0GQR1XS
DJM-1 M4\yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTRyLkm3PVkh|ryP MVHTRW5ITVJ?
TGBC11TKB Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHDTWM2OD12MT6wPVI3KM7:TR?= NFvMOFRUSU6JRWK=
U-2-OS NWDTem9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTR{LkK2OFEh|ryP NIfCWopUSU6JRWK=
NCI-H2030 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PK[2lEPTB;NEKuOFM3QCEQvF2= MVrTRW5ITVJ?
LU-135 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vHeGlEPTB;NEKuOVQ1PyEQvF2= MV3TRW5ITVJ?
ZR-75-30 MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXaPWlKSzVyPUSzMlA1QTNizszN NHPUT3ZUSU6JRWK=
GT3TKB MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL6SXdxUUN3ME20N{4zPjd7IN88US=> M2Dzb3NCVkeHUh?=
RPMI-2650 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\kZmlEPTB;NEOuO|gyPiEQvF2= MUHTRW5ITVJ?
SAS MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTR|Lkm1N|Qh|ryP NHGySFdUSU6JRWK=
MDA-MB-231 MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTafJBrUUN3ME20N{46PjB7IN88US=> NEH3Om9USU6JRWK=
JVM-3 M3G2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv2S|RCUUN3ME20OE4xPTN|IN88US=> MkntV2FPT0WU
COLO-320-HSR NYLXWZBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTR2LkW2N|Mh|ryP MontV2FPT0WU
SNB75 NWn5ZZJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTR2Lk[xNFUh|ryP M2PpRnNCVkeHUh?=
NCI-H441 M1nYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LwSmlEPTB;NESuPVMzQCEQvF2= MXrTRW5ITVJ?
HCT-116 Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LESmlEPTB;NESuPVg3QCEQvF2= NHPweXZUSU6JRWK=
NCI-H226 M{XFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPxTWM2OD12NT62N|Y5KM7:TR?= M3fSfXNCVkeHUh?=
CAL-33 NInoOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFmzR|dKSzVyPUS1MlkzOTdizszN MUTTRW5ITVJ?
NCI-H1437 NHnGdpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDnR2VKSzVyPUS2MlMzOSEQvF2= MXPTRW5ITVJ?
HCC1187 NEHNR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPtUnNKSzVyPUS2MlQzPTVizszN NY[1Nm1uW0GQR1XS
NUGC-3 NETGd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe5fnB[UUN3ME20Ok42PzB7IN88US=> MXXTRW5ITVJ?
T98G NFjiXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTR5LkW0O{DPxE1? MVnTRW5ITVJ?
OVCAR-8 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfhTWM2OD12Nz62PFMh|ryP NHnRU2NUSU6JRWK=
LB2241-RCC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHT[I1KSzVyPUS3MlczPyEQvF2= MmnMV2FPT0WU
NCI-H358 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn5TWM2OD12OD6xNVUzKM7:TR?= Mn2xV2FPT0WU
PANC-08-13 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke1TWM2OD12OD6xPFU{KM7:TR?= M37X[nNCVkeHUh?=
KP-N-YN MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTR6LkKxNFIh|ryP NWfrcXhFW0GQR1XS
NCI-H1755 NF7sNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW2boRKSzVyPUS4MlI4OjZizszN NHvEd4pUSU6JRWK=
NCI-N87 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTR6LkK5PVEh|ryP MkizV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pFGFR2 / FGFR2 ; 

PubMed: 24968263     


PD173074 and MK2461 inhibit FGFR2 phosphorylation. Cells were treated for 1 hour with a titration of PD173074 as described in Materials and methods. Lysates were prepared and 50 ug protein was subjected to SDS-PAGE and western blotting with phospho Y653/654 FGFR and MAB6841 total FGFR2 antibody.

p-S6RP / p-PRAS40 / p-p105 NFKB / P105 NFKB / P50 NFKB / p-AMPK / p-CRK II / p-PDK1; 

PubMed: 24968263     


Time course of inhibition for multiple signaling proteins. NCI-H716 cells were treated with 100 nM PD173074 for the indicated times and signaling pathways were analyzed by SDS PAGE and western blotting. 100 nM PD173074 was selected because this amount caused full inhibition of pERK at the 2 hour time point. “p” indicates phosphoprotein, and the phosphorylation sites are listed in Methods. Terminology on the right side of figure groups proteins according to the time at which inhibition or protein loss occurs.

24968263
Growth inhibition assay
Cell viability; 

PubMed: 24968263     


B. PD173074 and MK2461 inhibit NCI-H716 cell growth. Cell lines were plated at 4000 cells/well and incubated overnight. NCI-H716 cells were treated with a titration of PD173074 as described in Materials and Methods. Cell growth was measured with Vialight reagent, and growth was presented relative to untreated cells. C. PD173074 and MK2461 selectively inhibit growth of NCI-H716 cells. Colon cancer cell lines listed were plated at 4000 cells/well and 24 hours later were treated with a titration of compounds. 4 days later cell growth was measured with vialight and IC50s were calculated from graph pad prism. 

24968263
In vivo Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. [1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. [4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. [5]

Protocol

Kinase Assay:[1]
- Collapse

In vitro kinase inhibition assays:

Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl2, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-32P]ATP (5 μM ATP containing 0.4 μCi of [γ-32P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [32P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.
Cell Research:[4]
- Collapse
  • Cell lines: KMS11 and KMS18
  • Concentrations: Dissolved in DMSO, final concentrations ~100 nM
  • Incubation Time: 48 hours
  • Method: Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Swiss Webster mice with induced corneal angiogenesis
  • Dosages: ~2 mg/kg/day
  • Administration: Administered intraperitoneally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (190.95 mM)
Ethanol 100 mg/mL (190.95 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 523.67
Formula

C28H41N7O3

CAS No. 219580-11-7
Storage powder
in solvent
Synonyms N/A
Smiles CCN(CC)CCCCNC1=NC=C2C=C(C(=NC2=N1)NC(=O)NC(C)(C)C)C3=CC(=CC(=C3)OC)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the half-life of PD173074(S1264) in vivo?

  • Answer:

    According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Related FGFR Products

Tags: buy PD173074|PD173074 ic50|PD173074 price|PD173074 cost|PD173074 solubility dmso|PD173074 purchase|PD173074 manufacturer|PD173074 research buy|PD173074 order|PD173074 mouse|PD173074 chemical structure|PD173074 mw|PD173074 molecular weight|PD173074 datasheet|PD173074 supplier|PD173074 in vitro|PD173074 cell line|PD173074 concentration|PD173074 nmr|PD173074 in vivo|PD173074 clinical trial|PD173074 inhibitor|PD173074 Angiogenesis inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID